GlobeNewswire, Inc.

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac...

GlobeNewswire, Inc.

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in...

GlobeNewswire, Inc.

Durham, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Phase 2 GenePHIT trial successfully randomized and completed enrollment of one of the largest gene therapy trials conducted in heart failure to date, with more than 170 participants randomized across...

EIN Presswire

GA, UNITED STATES, August 28, 2026 /⁨EINPresswire.com⁩/ -- Imagine electronic devices that stretch, bend, and conform to the human body like a second skin—yet still deliver high-performance optical sensing and display capabilities.

Kentucky Educational Television

For Release: 08/27/26 10:58 AM On a new episode of Kentucky Tonight, airing Monday, Aug. 31, Chip Polston will host a discussion of how Name, Image and Likeness (NIL) is changing college sports in the Commonwealth.

GlobeNewswire, Inc.

Manchester, LANCS, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Purple, the global guest, staff and multi-tenant WiFi and analytics platform, has been awarded a place on the UK Government's G-Cloud 15 framework.